STOCK TITAN

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

ChromaDex Corp. (NASDAQ:CDXC) has announced it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after market close. The company will host an investor conference call to discuss the results and provide a business update on Wednesday, November 6, 2024, at 4:30 p.m. ET. Management encourages participants to join 10 minutes before the call. A replay will be available from 7:30 p.m. EDT on November 6 until 11:59 p.m. EDT on November 13, 2024.

ChromaDex Corp. (NASDAQ:CDXC) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 giovedì 31 ottobre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call per gli investitori per discutere i risultati e fornire un aggiornamento sull'andamento aziendale mercoledì 6 novembre 2024, alle 16:30 ET. La direzione incoraggia i partecipanti a unirsi 10 minuti prima della chiamata. La registrazione sarà disponibile dalle 19:30 EDT del 6 novembre fino alle 23:59 EDT del 13 novembre 2024.

ChromaDex Corp. (NASDAQ:CDXC) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 31 de octubre de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica con inversores para discutir los resultados y proporcionar una actualización del negocio el miércoles 6 de noviembre de 2024, a las 4:30 p.m. ET. La dirección anima a los participantes a unirse 10 minutos antes de la llamada. Una repetición estará disponible desde las 7:30 p.m. EDT del 6 de noviembre hasta las 11:59 p.m. EDT del 13 de noviembre de 2024.

ChromaDex Corp. (NASDAQ:CDXC)는 2024년 10월 31일 목요일 시장 종료 후 2024년 3분기 재무 결과를 발표한다고 발표했습니다. 회사는 2024년 11월 6일 수요일 오후 4:30 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 투자자 컨퍼런스 콜을 개최할 것입니다. 경영진은 참가자들이 전화 10분 전에 참여할 것을 권장합니다. 재생은 11월 6일 오후 7:30 EDT부터 2024년 11월 13일 오후 11:59 EDT까지 이용 가능합니다.

ChromaDex Corp. (NASDAQ:CDXC) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le jeudi 31 octobre 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique pour les investisseurs le mercredi 6 novembre 2024, à 16h30 ET, pour discuter des résultats et fournir une mise à jour sur les affaires. La direction encourage les participants à se connecter 10 minutes avant l'appel. Un enregistrement sera disponible à partir de 19h30 EDT le 6 novembre jusqu'à 23h59 EDT le 13 novembre 2024.

ChromaDex Corp. (NASDAQ:CDXC) hat angekündigt, dass die Finanzergebnisse für das dritte Quartal 2024 am Donnerstag, dem 31. Oktober 2024, nach Börsenschluss veröffentlicht werden. Das Unternehmen wird am Mittwoch, dem 6. November 2024, um 16:30 Uhr ET eine Telefonkonferenz für Investoren abhalten, um die Ergebnisse zu besprechen und ein Update zum Geschäft zu geben. Das Management ermutigt die Teilnehmer, sich 10 Minuten vor der Konferenz einzuwählen. Eine Wiederholung wird vom 6. November, 19:30 EDT bis zum 13. November, 23:59 EDT 2024 verfügbar sein.

Positive
  • None.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024.

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Wednesday, November 6, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:

Date: Wednesday, November 6, 2024

Time: 4:30 p.m. ET (1:30 p.m. PT)

Toll-free dial-in number: 1-888-596-4144

Conference ID: 8584242

Webcast link: ChromaDex Third Quarter 2024 Earnings Conference Call

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available from 7:30 p.m. EDT on November 6, 2024, to 11:59 p.m. EDT on Wednesday, November 13, 2024. The replay dial-in information is as follows:

Toll-free replay number: 1-800-770-2030

Replay ID: 8584242#

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex supplies pharmaceutical-grade Niagen® to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen® for clinics. These pharmaceutical-grade Niagen® products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com

Source: ChromaDex Corporation

FAQ

When will ChromaDex (CDXC) report Q3 2024 earnings?

ChromaDex will report its third quarter 2024 financial results on Thursday, October 31, 2024, after market close.

When is ChromaDex's (CDXC) Q3 2024 earnings call?

ChromaDex will host its Q3 2024 earnings conference call on Wednesday, November 6, 2024, at 4:30 p.m. ET.

How can I access ChromaDex's (CDXC) Q3 2024 earnings call?

Investors can access the call using the toll-free number 1-888-596-4144 with Conference ID: 8584242, or via the webcast link available on ChromaDex's investor relations website.

How long will ChromaDex's (CDXC) Q3 2024 earnings call replay be available?

The earnings call replay will be available from November 6, 2024, at 7:30 p.m. EDT until November 13, 2024, at 11:59 p.m. EDT.

ChromaDex Corporation

NASDAQ:CDXC

CDXC Rankings

CDXC Latest News

CDXC Stock Data

468.11M
75.93M
35.6%
22.63%
3.9%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States of America
LOS ANGELES